The global stem cell industry is experiencing a period of rapid technological and clinical expansion. Beyond traditional hematopoietic applications, novel platforms such as CAR-T cell therapies, induced pluripotent stem cells (iPSCs), mesenchymal stem cells, and exosome-based therapeutics are reshaping the landscape of regenerative medicine. Each modality introduces unique clinical workflows, manufacturing challenges, and regulatory requirements, positioning the workforce as a critical enabler of market growth. [Read more…]
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
Announcement Highlights:
- Patient enrolment has been completed in Cynata’s Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
- The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
- Primary evaluation period expected to complete in March 2026, with results in June 2026.
- CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.
Cord Blood Banking Industry – Key Benchmarks to Track & Why to Care
The “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” market report reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the  cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.
Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.
[Read more…]
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
Singapore, 12 December 2025 – Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program.  Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. [Read more…]
Who Is CryoHoldco? Latin America’s Largest Cord Blood Bank
CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and the fifth largest cord blood banks globally. CryoHoldco is also many times larger than any other stem cell bank in Latin America, with over 400,000 stem cell units in storage.
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 338
- Next Page »